Your request to link to rcsb for Glycogen%20synthase%20kinase-3%20beta

• 1GNG: glycogen synthase kinase-3 beta (gsk3) complex with frattide peptide (10.1016/S0969-2126(01)00679-7 )
• 1H8F: glycogen synthase kinase 3 beta. (10.1016/S0092-8674(01)00374-9 )
• 1I09: structure of glycogen synthase kinase-3 (gsk3b) (10.1038/89624 )
• 1J1B: binary complex structure of human tau protein kinase i with amppnp (10.1107/S090744490302938X )
• 1J1C: binary complex structure of human tau protein kinase i with adp (10.1107/S090744490302938X )
• 1O9U: glycogen synthase kinase 3 beta complexed with axin peptide (10.1093/EMBOJ/CDG068 )
• 1PYX: gsk-3 beta complexed with amp-pnp (10.1016/J.JMB.2003.08.031 )
• 1Q3D: gsk-3 beta complexed with staurosporine (10.1016/J.JMB.2003.08.031 )
• 1Q3W: gsk-3 beta complexed with alsterpaullone (10.1016/J.JMB.2003.08.031 )
• 1Q41: gsk-3 beta complexed with indirubin-3'-monoxime (10.1016/J.JMB.2003.08.031 )
• 1Q4L: gsk-3 beta complexed with inhibitor i-5 (10.1016/J.JMB.2003.08.031 )
• 1Q5K: crystal structure of glycogen synthase kinase 3 in complexed with inhibitor (10.1074/JBC.M306268200 )
• 1R0E: glycogen synthase kinase-3 beta in complex with 3-indolyl-4- arylmaleimide inhibitor
• 1UV5: glycogen synthase kinase 3 beta complexed with 6-bromoindirubin-3'- oxime (10.1016/J.CHEMBIOL.2003.11.010 )
• 2JLD: extremely tight binding of ruthenium complex to glycogen synthase kinase 3 (10.1002/CBIC.200800489 )
• 2O5K: crystal structure of gsk3beta in complex with a benzoimidazol inhibitor (10.1016/J.BMCL.2007.07.056 )
• 2OW3: glycogen synthase kinase-3 beta in complex with bis-(indole)maleimide pyridinophane inhibitor (10.1016/J.BMCL.2007.02.059 )
• 3DU8: crystal structure of gsk-3 beta in complex with nms-869553a (10.1021/JM800977Q )
• 3F7Z: x-ray co-crystal structure of glycogen synthase kinase 3beta in complex with an inhibitor (10.1016/J.BMC.2009.01.019 )
• 3F88: glycogen synthase kinase 3beta inhibitor complex (10.1016/J.BMC.2009.01.019 )
• 3GB2: gsk3beta inhibitor complex (10.1021/JM900647E )
• 3I4B: crystal structure of gsk3b in complex with a pyrimidylpyrrole inhibitor (10.1021/JM900630Q )
• 3L1S: 3-aryl-4-(arylhydrazono)-1h-pyrazol-5-ones: highly ligand efficient and potent inhibitors of gsk3 (10.1016/J.BMCL.2010.01.072 )
• 3M1S: structure of ruthenium half-sandwich complex bound to glycogen synthase kinase 3 (10.1007/S00775-010-0699-X )
• 3PUP: structure of glycogen synthase kinase 3 beta (gsk3b) in complex with a ruthenium octasporine ligand (os1) (10.1021/JA1112996 )
• 3Q3B: 6-amino-4-(pyrimidin-4-yl)pyridones: novel glycogen synthase kinase-3 inhibitors (10.1016/J.BMCL.2011.01.017 )
• 3SAY: crystal structure of human glycogen synthase kinase 3 beta (gsk3b) in complex with inhibitor 142
• 3SD0: identification of a glycogen synthase kinase-3b inhibitor that attenuates hyperactivity in clock mutant mice
• 3ZDI: glycogen synthase kinase 3 beta complexed with axin peptide and inhibitor 7d (10.1021/JM301575N )
• 3ZRK: identification of 2-(4-pyridyl)thienopyridinones as gsk-3beta inhibitors (10.1016/J.BMCL.2011.06.050 )
• 3ZRL: identification of 2-(4-pyridyl)thienopyridinones as gsk-3beta inhibitors (10.1016/J.BMCL.2011.06.050 )
• 3ZRM: identification of 2-(4-pyridyl)thienopyridinones as gsk- 3beta inhibitors (10.1016/J.BMCL.2011.06.050 )
• 4ACC: gsk3b in complex with inhibitor (10.1021/JM201724M )
• 4ACD: gsk3b in complex with inhibitor (10.1021/JM201724M )
• 4ACG: gsk3b in complex with inhibitor (10.1021/JM201724M )
• 4ACH: gsk3b in complex with inhibitor (10.1021/JM201724M )
• 4AFJ: 5-aryl-4-carboxamide-1,3-oxazoles: potent and selective gsk-3 inhibitors (10.1016/J.BMCL.2012.01.034 )
• 4B7T: glycogen synthase kinase 3 beta complexed with axin peptide and leucettine l4 (10.1021/JM301034U )
• 4DIT: crystal structure of gsk3beta in complex with a imidazopyridine inhibitor 29-feb-12 4dit 1 title
• 4IQ6: gsk-3beta with inhibitor 6-chloro-n-cyclohexyl-4-(1h-pyrrolo[2,3- b]pyridin-3-yl)pyridin-2-amine (10.1021/ML300348C )
• 4J1R: crystal structure of gsk3b in complex with inhibitor 15r
• 4J71: crystal structure of gsk3b in complex with inhibitor 1r
• 4NM0: crystal structure of peptide inhibitor-free gsk-3/axin complex
• 4NM3: crystal structure of gsk-3/axin complex bound to phosphorylated n- terminal auto-inhibitory ps9 peptide
• 4NM5: crystal structure of gsk-3/axin complex bound to phosphorylated wnt receptor lrp6 c-motif
• 4NM7: crystal structure of gsk-3/axin complex bound to phosphorylated wnt receptor lrp6 e-motif
• 4NU1: crystal structure of a transition state mimic of the gsk-3/axin complex bound to phosphorylated n-terminal auto-inhibitory ps9 peptide
• 4PTC: structure of a carboxamide compound (3) (2-{2-[(cyclopropylcarbonyl) amino]pyridin-4-yl}-4-oxo-4h-1lambda~4~,3-thiazole-5-carboxamide) to gsk3b (10.1016/J.BMCL.2015.03.046 )
• 4PTE: structure of a carvoxamide compound (15) (n-[4-(isoquinolin-7-yl) pyridin-2-yl]cyclopropanecarboxamide) to gsk3b (10.1016/J.BMCL.2015.03.046 )
• 4PTG: structure of a carboxamine compound (26) (2-{2-[(cyclopropylcarbonyl) amino]pyridin-4-yl}-4-methoxypyrimidine-5-carboxamide) to gsk3b (10.1016/J.BMCL.2015.03.046 )
• 5AIR: structural analysis of mouse gsk3beta fused with lrp6 peptide.
• 5F94: crystal structure of gsk3b in complex with compound 15: 2- [(cyclopropylcarbonyl)amino]-n-(4-methoxypyridin-3-yl)pyridine-4- carboxamide (10.1021/ACS.JMEDCHEM.5B01550 )
• 5F95: crystal structure of gsk3b in complex with compound 18: 2- [(cyclopropylcarbonyl)amino]-n-(4-phenylpyridin-3-yl)pyridine-4- carboxamide (10.1021/ACS.JMEDCHEM.5B01550 )
• 5HLN: x-ray crystal structure of gsk3b in complex with chir99021 (10.1021/ACSCHEMBIO.6B00306 )
• 5HLP: x-ray crystal structure of gsk3b in complex with brd3937 (10.1021/ACSCHEMBIO.6B00306 )
• 5K5N: crystal structure of gsk-3beta complexed with pf-04802367, a highly selective brain-penetrant kinase inhibitor (10.1002/ANIE.201603797 )
• 5KPK: glycogen synthase kinase 3 beta complexed with brd0209 (10.1126/SCITRANSLMED.AAM8460 )
• 5KPL: glycogen synthase kinase 3 beta complexed with brd0705 (10.1126/SCITRANSLMED.AAM8460 )
• 5KPM: glycogen synthase kinase 3 beta complexed with brd3731 (10.1126/SCITRANSLMED.AAM8460 )
• 5OY4: gsk3beta complex with n-(6-(3,4-dihydroxyphenyl)-1h-pyrazolo[3,4- b]pyridin-3-yl)acetamide (10.1021/ACSMEDCHEMLETT.7B00296 )
• 5T31: exploiting an asp-glu switch in glycogen synthase kinase 3 to design paralog selective inhibitors for use in acute myeloid leukemia (10.1126/SCITRANSLMED.AAM8460 )
• 6AE3: crystal structure of gsk3beta complexed with morin (10.1016/J.BBRC.2018.08.182 )
• 6B8J: co-structure of human glycogen synthase kinase beta with a selective (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino) ethyl]amine inhibitor (10.1021/ACS.JMEDCHEM.7B00922 )
• 6GJO: crystal structure of glycogen synthase kinase-3 beta in complex with bi-91bs
• 6GN1: crystal structure of glycogen synthase kinase-3 beta (gsk3b) in complex with pik-75 (10.1002/ANIE.201804917 )
• 6H0U: glycogen synthase kinase-3 beta (gsk3) complex with a covalent [1,2, 4]triazolo[1,5-a][1,3,5]triazine inhibitor (10.1002/CMDC.201800778 )
• 6HK3: crystal structure of gsk-3b in complex with pyrazine inhibitor c44 (10.1021/ACS.JCTC.9B00104 )
• 6HK4: crystal structure of gsk-3b in complex with pyrazine inhibitor c22 (10.1021/ACS.JCTC.9B00104 )
• 6HK7: crystal structure of gsk-3b in complex with pyrazine inhibitor c50 (10.1021/ACS.JCTC.9B00104 )
• 6TCU: glycogen synthase kinase-3 beta (gsk3b) in complex with ligand 1 (10.1021/ACSMEDCHEMLETT.9B00633 )
• 6V6L: co-structure of human glycogen synthase kinase beta with 1-(6-((2-((6- amino-5-nitropyridin-2-yl)amino)ethyl)amino)-2-(2,4-dichlorophenyl) pyridin-3-yl)-4-methylpiperazin-2-one (10.1016/J.BMCL.2019.126930 )
• 6Y9R: crystal structure of gsk-3b in complex with the 1h-indazole-3- carboxamide inhibitor 2 (10.3390/MOLECULES25092163 )
• 6Y9S: crystal structure of gsk-3b in complex with the imidazo[1,5- a]pyridine-3-carboxamide inhibitor 16 (10.3390/MOLECULES25092163 )
• 7B6F: gsk3-beta in complex with compound (s)-5c
• 7OY5: crystal structure of gsk3beta in complex with arn25068 (10.1016/J.EJMECH.2021.114054 )